ArticleScientific reports2026
Synthesis, characterization, DFT analysis, molecular docking and anticancer investigations in colorectal carcinoma of a novel pyrazole-hydrazone zinc(II) complex.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Monomeric Zn(II) and 3D polymeric Ag(I) complexes with a cationic s-triazine hydrazone-based ligand; synthesis, structure, coordination behavior and biological studies.Scientific reports · 2026Article
- Complexes of Zinc(II) Chloride withPharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The IMP ligand and its Zn(II) complex were characterized by different spectroscopic techniques, such as FT-IR, MS and NMR spectroscopy. Density functional theory (DFT) calculations were used to elucidate their structural and electronic properties. The cytotoxic potential of both compounds was evaluated against the human colorectal carcinoma HCT116 cell line. The zinc(II) complex exhibited significantly enhanced antiproliferative activity compared to the free ligand, with an IC50 value of 24.56 μM after 48 h, while showing no cytotoxicity toward normal HEK293 cells. Colony formation and cell cycle analyses revealed that IMP-Zn significantly suppressed clonogenic growth and induced SubG0 phase accumulation, suggesting apoptosis-associated cell death. Molecular docking studies demonstrated stronger binding affinity of the zinc complex toward cancer-related molecular targets, supporting the experimental findings. Overall, these observations indicate that coordination of the pyrazole–hydrazone ligand to Zn(II) enhances its anticancer activity, highlighting IMP-Zn as a promising zinc-based metallotherapeutic candidate for colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.